Sampling over decades
Professor Harri Lähdesmäki is a specialist in the development and application of computational tools for studying biomarkers for better predictive care. His team typically works with the massive data sets generated by mass spectrometry and gene sequencing.
‘We collaborate a lot with biologists and medical doctors to analyse huge sets of biological data collected from cohorts that include both healthy people and people who have a specific condition,’ he says.
‘There are studies in Finland that collect nasal, blood, stool and other bio samples from volunteers starting at birth and continuing into adulthood, so that medical doctors can try to better understand disease causality and progression.’
One of the team's most influential findings comes from a long-term study looking at how the bacteria in children's gut influences their overall health and immunity, specifically in relation to the onset of type 1 diabetes. While the root cause of type 1 diabetes remains a mystery, the team's findings reinforce the view that gut health plays a key role in triggering the condition.
The study looked at the gut bacteria of children in three cities: Espoo in Finland, Tartu in Estonia, and Petrozavodsk in Russian Karelia. The locations were chosen as their populations are genetically similar, yet they are geographically diverse enough to reveal the role of environmental factors in the development of gut bacteria.
Lähdesmäki and his colleagues found that the bacteria responsible for producing molecules called lipopolysaccharides ― known to inhibit the human immune system ― are highly abundant in children in Finland and Estonia, but much less so in Russian Karelia. This led the research group to the hypothesis that children in Finland and Estonia have an increased risk of an inhibited immune system, and thus of contracting diseases like type 1 diabetes. It helps to explain why the incidence of auto-immune diseases is approximately five-fold higher in Finland and Estonia than in Russian Karelia.
The hypothesis was confirmed through a controlled model using mice. The mice exposed to the lipopolysaccharide-producing bacteria present in Finnish and Estonian children developed type 1 diabetes at a significantly higher rate than those not exposed to the bacteria.
‘The findings from the sequencing data came via the use of computational techniques, and were then experimentally tested in a lab,’ says Lähdesmäki. ‘This was highly interdisciplinary work that involved close collaboration between teams in several countries, including representatives from the Broad Institute of MIT and Harvard University.’
A medical vision comes of age
Lähdesmäki says Finland's approach to bio-medical studies is unique, in that some projects have been going on as long as 25 years and have taken samples from tens of thousands of people.
‘Biomedical research in Finland wouldn't be as competitive as it is today without visionary medical doctors like Mikael Knip, Sture Andersson and several others,’ he says.
‘Given Finland's biomedical expertise, extensive biobanks and our national healthcare system ― together with Aalto University's world-leading research capability in statistical data analysis and artificial intelligence ― the country is in an excellent position to continue making a significant scientific impact as health and medicine go digital.’
Text: Andrew Flowers